热门资讯> 正文
Legend Biotech、强生墨水Carvykti供应协议
2025-10-08 05:12
- 纳比特(NA) 0
- 盛大科技(SDA) 0
- 传奇生物(LEGN) 0
- Legend Biotech (NASDAQ:LEGN) and Johnson & Johnson's (NYSE:JNJ) Janssen Pharmaceuticals division have signed a component and product supply agreement for Carvykti (ciltacabtagene autoleucel) under which the former will manufacture for the latter the CAR-T treatment for clinical and commercial use globally except for greater China.
- The arrangement replaces a temporary agreement signed by the two companies on Feb. 28, 2022.
- Terms call for Janssen to pay Legend a transfer price for Carvykti that reflects the therapy's production cost, plus a markup. However, the total costs necessary for production will be shared equally.
- Janssen will also supply Legend Biotech with lentivirus, unprocessed cells, and certain other raw materials at a price equivalent to Janssen's total costs to do so, plus a markup.
More on Legend Biotech, Johnson & Johnson
- Johnson & Johnson (JNJ) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
- Johnson & Johnson (JNJ) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
- Legend Biotech Corporation (LEGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
- J&J hit with $966M jury award in Los Angeles over talc-related cancer case
- J&J posts long-term trial data for injectable Tremfya in ulcerative colitis
推荐文章
美股机会日报 | TACO交易重现？美股三大指数期货盘前齐涨；大摩看好AI需求高调唱多英伟达
10月财报预告 | 美股新一轮财报季即将打响！高盛、摩根大通打头阵；特斯拉、谷歌、苹果等紧随其后
新股申购 | 聚水潭今日起招股！入场费3090.85港元
出手就涨200%！特朗普政府疯狂抢购这类公司，下一个幸运儿是谁？
美股机会日报 | 特斯拉中国销量止跌回升；高通涉嫌违反反垄断法！被立案调査
从Fitness+到Health+ 苹果(AAPL.US)健康与健身业务迎来整合
美联储鲍曼召集“非常规”会议 社区银行改革路径引猜测
10月10日外盘头条：特斯拉FSD再遭联邦安全调查 法拉利股价暴跌 美国财政部干预阿根廷外汇市场
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
